PURPOSE: The purpose of this study was to review the monitoring of strontium ranelate osteoporosis therapy. METHODS: The method used in this study was comprehensive literature review with clinical perspectives. RESULTS: Changes in bone turnover markers (BTM) or bone mineral density (BMD) have been documented in osteoporosis clinical trials. However, neither BMD nor BTM changes fully explain the observed fracture risk reduction in treated patients. If changes in BMD or BTM on therapy would be easily discernable in individual patients, and were strongly associated with fracture risk reduction, monitoring individuals would be more useful. BMD changes in patients on strontium ranelate are of a greater magnitude and hence can be easily determined in an individual patient. In addition, there exists a better correlation between fracture risk reduction and increases in BMD. CONCLUSIONS: The strong correlation between measured BMD increases and fracture risk reduction in patients on strontium ranelate therapy will be of clinical benefit to physicians wishing to evaluate both treatment persistence and fracture risk reduction.
PURPOSE: The purpose of this study was to review the monitoring of strontium ranelateosteoporosis therapy. METHODS: The method used in this study was comprehensive literature review with clinical perspectives. RESULTS: Changes in bone turnover markers (BTM) or bone mineral density (BMD) have been documented in osteoporosis clinical trials. However, neither BMD nor BTM changes fully explain the observed fracture risk reduction in treated patients. If changes in BMD or BTM on therapy would be easily discernable in individual patients, and were strongly associated with fracture risk reduction, monitoring individuals would be more useful. BMD changes in patients on strontium ranelate are of a greater magnitude and hence can be easily determined in an individual patient. In addition, there exists a better correlation between fracture risk reduction and increases in BMD. CONCLUSIONS: The strong correlation between measured BMD increases and fracture risk reduction in patients on strontium ranelate therapy will be of clinical benefit to physicians wishing to evaluate both treatment persistence and fracture risk reduction.
Authors: Paul D Miller; Michael R McClung; Liviu Macovei; Jacob A Stakkestad; Marjorie Luckey; Bernard Bonvoisin; Jean-Yves Reginster; Robert R Recker; Claire Hughes; E Michael Lewiecki; Dieter Felsenberg; Pierre D Delmas; David L Kendler; Michael A Bolognese; Nicole Mairon; Cyrus Cooper Journal: J Bone Miner Res Date: 2005-03-14 Impact factor: 6.741
Authors: Delphine Farlay; Georges Boivin; Gérard Panczer; Agnès Lalande; Pierre Jean Meunier Journal: J Bone Miner Res Date: 2005-04-27 Impact factor: 6.741
Authors: S G Dahl; P Allain; P J Marie; Y Mauras; G Boivin; P Ammann; Y Tsouderos; P D Delmas; C Christiansen Journal: Bone Date: 2001-04 Impact factor: 4.398
Authors: Somnath Sarkar; Bruce H Mitlak; Mayme Wong; John L Stock; Dennis M Black; Kristine D Harper Journal: J Bone Miner Res Date: 2002-01 Impact factor: 6.741
Authors: S P Nielsen; D Slosman; O H Sørensen; B Basse-Cathalinat; P De Cassin; C R Roux; P J Meunier Journal: J Clin Densitom Date: 1999 Impact factor: 2.963
Authors: Nelson B Watts; Cyrus Cooper; Robert Lindsay; Richard Eastell; Michael D Manhart; Ian P Barton; Tjeerd-Pieter van Staa; Jonathan D Adachi Journal: J Clin Densitom Date: 2004 Impact factor: 2.963
Authors: Chen Zhang; Cassandra L Miller; Rakshya Gorkhali; Juan Zou; Kenneth Huang; Edward M Brown; Jenny J Yang Journal: Front Physiol Date: 2016-09-30 Impact factor: 4.566